UMIN-ICDS Clinical Trial

Unique ID issued by UMIN UMIN000048125
Receipt number R000054845
Scientific Title DEtecting MicrovAscular dysfunction with Non-obstructive coronary artery Disease in Heart Failure - Multi-center, prospective, observational study -
Date of disclosure of the study information 2022/06/21
Last modified on 2022/06/21 18:23:35

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

DEtecting MicrovAscular dysfunction with Non-obstructive coronary artery Disease in Heart Failure

Acronym

DEMAND-HF

Scientific Title

DEtecting MicrovAscular dysfunction with Non-obstructive coronary artery Disease in Heart Failure
- Multi-center, prospective, observational study -

Scientific Title:Acronym

DEMAND-HF

Region

Japan


Condition

Condition

patients with heart failure and non-obstructive coronary artery disease (HF-NOCA)

Classification by specialty

Cardiology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

This study aims to explore the prevalence and degrees of coronary microvascular dysfunction (CMD) and to investigate their associations with clinical outcomes as well as clinical and pathological characteristics in subjects with HF-NOCA.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

The primary endpoint is a composite of worsening heart failure or cardiovascular death and the associations of the presence and degrees of CMD with the primary endpoint will be investigated. An episode of worsening heart failure is either an unplanned hospitalization or more than or equal to 2 points of the following criteria: 1) worsening symptom of heart failure, 2) congestion on chest X-ray, and 3) significant increases in BNP or NT-pro BNP.

Key secondary outcomes

Key secondary endpoints are the following variables, and their associations with the presence and degrees of CMD will be assessed.
1) a composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal cerebral vascular disease
2) a composite of all-cause death or hospitalization for heart failure
3) hospitalization for heart failure, including repeat admission
4) newly developed arrhythmia such as atrial fibrillation
5) The primary endpoint will be also evaluated in the subgroup analyses stratified by LVEF (i.e., heart failure with preserved or reduced LVEF)

Additional secondary endpoints are as follows, and compared between the groups stratified by the presence and degrees of CMD.
1) Time courses of parameters of echocardiography (LVEF, LVDd, LVDs, LAD, E/A, E/e, etc.)
2) Hemodynamic indexes (cardiac index, pulmonary artery wedge pressure, pulmonary artery pressure, right ventricular pressure, right atrial pressure, end-diastolic left ventricular pressure, Tau, etc.)
3) Pathological indexes from the right ventricular endomyocardial biopsy


Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1) Patient with greater than or equal to 20 years of age.
2) Patient who has been informed of the study and has provided written informed consent, approved by the appropriate Institutional Review Board (IRB)/ Ethics Committee (EC) of the respective clinical sites.
3) Patient who underwent coronary angiography and physiological assessments during the index HF admission.
4) Patient who agrees to undergo all protocol-requiring follow-up examinations and requirements at the investigational site.
5) Patient with any left ventricular ejection fraction (LVEF) level is eligible.

Key exclusion criteria

1) Patient with heart failure due to ischemic heart disease defined as prior myocardial infarction and/or significant obstructive coronary artery at coronary artery trees defined as stenosis greater than or equal to 75% on visual evaluation and/or fractional flow reserve (FFR) less than or equal to 0.8.
2) Patient with severe valvular heart disease.
3) Patient with congenital heart disease.
4) Patient with chronic kidney disease (eGFR less than 30 ml/min/1.73m2) or on chronic hemodialysis (and/or peritoneal dialysis).
5) Patient with heart failure due to hyperthyroidism.
6) Patient with persistent tachycardia (heart rate greater than or equal to 100bpm) at the evaluation of coronary physiology.
7) Patient with heart failure due to severe anemia less than 8.0 g/dl or requiring blood transfusion.
8) Patient who cannot regularly visit a hospital or patient with a life expectancy less than or equal to 24 months due to terminally non-cardiac illness.

Target sample size

500


Research contact person

Name of lead principal investigator

1st name Kiyoshi
Middle name
Last name Hibi

Organization

Yokohama City University Medical Center

Division name

Division of Cardiology

Zip code

232-0024

Address

4-57, Urafune-cho, Minami-ku, Yokohama

TEL

045-261-5656

Email

hibikiyo@urahp.yokohama-cu.ac.jp


Public contact

Name of contact person

1st name Kozo
Middle name
Last name Okada

Organization

Yokohama City University Medical Center

Division name

Division of Cardiology

Zip code

232-0024

Address

4-57, Urafune-cho, Minami-ku, Yokohama

TEL

045-261-5656

Homepage URL


Email

kokada2@yokohama-cu.ac.jp


Sponsor or person

Institute

Yokohama City University Medical Center

Institute

Department

Personal name



Funding Source

Organization

Kanagawa PTCA Research Association

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Yokohama City University

Address

3-9, Fukuura, kanazawa-ku, Yokohama, Japan

Tel

045-370-7627

Email

rinri@yokohama-cu.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2022 Year 06 Month 21 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Enrolling by invitation

Date of protocol fixation

2021 Year 03 Month 16 Day

Date of IRB

2021 Year 05 Month 21 Day

Anticipated trial start date

2021 Year 12 Month 20 Day

Last follow-up date

2026 Year 12 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

Multi-center, prospective, observational study

Coronary angiographic and physiological data will be analyzed at the Cardiovascular Core Analysis Laboratory, Stanford University School of Medicine in the USA.

Right or left ventricular endomyocardial biopsy will be analyzed at National Cerebral and Cardiovascular Center in Japan.


Management information

Registered date

2022 Year 06 Month 21 Day

Last modified on

2022 Year 06 Month 21 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000054845


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name